FDA says Moderna (MRNA) exposed participants, age 65 and over, to increased risk of severe illness by giving them a sub standard of care against the recommendation of FDA career scientists

FDA says Moderna (MRNA) exposed participants, age 65 and over, to increased risk of severe illness by giving them a sub standard of care against the recommendation of FDA career scientists.

The FDA's statement regarding Moderna suggests significant regulatory scrutiny and potential reputational damage for the company, which could lead to market volatility. This development raises concerns about compliance with safety protocols, potentially impacting investor sentiment and regulatory actions against Moderna. Watch for implications on Moderna's stock performance and how this may influence broader market dynamics in the biotechnology sector.